Bristol Myers Squibb (CELG-RI) Buildings (2015 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Buildings of $7.9 billion for Q2 2026, up 15.73% year-over-year from $6.9 billion in Q2 2025, and up 5.97% quarter-over-quarter from $7.5 billion in Q1 2026.
Bristol Myers Squibb (CELG-RI) Buildings (2015 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Buildings for 12 consecutive years, with $7.9 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Buildings rose 15.73% year-over-year to $7.9 billion; the TTM figure through Jun 2026 stood at $7.9 billion (up 15.73% YoY), while the FY2025 annual figure was $7.3 billion, up 10.47% from the prior year.
- Buildings grew to $7.9 billion in Q2 2026 per CELG-RI's latest filing, from $7.5 billion in the prior quarter.
- Across five years, Buildings topped out at $7.9 billion in Q2 2026 and bottomed at $5.7 billion in Q2 2022.
- Historically, Buildings has averaged $6.5 billion across 5 years, with a median of $6.5 billion in 2023.
- Annual changes were most pronounced in 2022 — Buildings climbed 0.09% — and 2026, when it grew 15.73%.
- Bristol Myers Squibb's Buildings stood at $5.9 billion in 2022, then rose by 9.71% to $6.5 billion in 2023, then gained by 1.32% to $6.6 billion in 2024, then gained by 10.47% to $7.3 billion in 2025, then climbed by 9.12% to $7.9 billion in 2026.
- Business Quant data shows CELG-RI's Buildings at $7.9 billion in Q2 2026, $7.5 billion in Q1 2026, and $7.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.93 Bn |
| Mar 31, 2026 | 7.49 Bn |
| Dec 31, 2025 | 7.27 Bn |
| Sep 30, 2025 | 7.12 Bn |
| Jun 30, 2025 | 6.86 Bn |
| Mar 31, 2025 | 6.64 Bn |
| Dec 31, 2024 | 6.58 Bn |
| Sep 30, 2024 | 6.47 Bn |
| Jun 30, 2024 | 6.67 Bn |
| Mar 31, 2024 | 6.55 Bn |
| Dec 31, 2023 | 6.50 Bn |
| Sep 30, 2023 | 6.28 Bn |
| Jun 30, 2023 | 6.04 Bn |
| Mar 31, 2023 | 5.99 Bn |
| Dec 31, 2022 | 5.92 Bn |
| Sep 30, 2022 | 5.75 Bn |
| Jun 30, 2022 | 5.74 Bn |
| Mar 31, 2022 | 5.94 Bn |
| Dec 31, 2021 | 5.90 Bn |
| Sep 30, 2021 | 5.74 Bn |